Truist Securities upgraded Inspire Medical Systems Inc (INSP) to Buy from Hold on November 25, 2025. The stock is currently priced at $127.33.
This upgrade reflects a more optimistic outlook on Inspire Medical Systems' prospects. The company's focus on developing innovative, minimally invasive solutions for patients with obstructive sleep apnea is underscored by its proprietary Inspire therapy, which is FDA, EU MDR, and PDMA-approved.
Inspire Medical Systems, headquartered in Golden Valley, Minnesota, has a market capitalization of $2.4 billion and a trailing twelve-month price-to-earnings ratio of 53.89, with earnings per share at $1.47. The firm is expected to report earnings on August 3, 2026, with an estimated EPS of $0.33 and revenue of $248.9 million.
Analyst ratings and price targets are professional opinions based on research and financial models. While they can offer useful perspectives, they represent assumptions that may not materialize as expected. Investment decisions should consider multiple factors, including company fundamentals and industry trends.
As of November 1, 2025, the analyst consensus for Inspire Medical Systems stands at 4 Strong Buy, 10 Buy, and 12 Hold ratings, with no Sell or Strong Sell ratings among the 26 total analysts. Recent upgrades from other analysts include Wolfe Research and Stifel, both of which have also raised their ratings recently.